Financials
Financial year 2025
BF Resp Oncology from Overijse, company number BE1013959311, closed financial year 2025 with a result of € 317,166 after tax. For that financial year BF Resp Oncology recorded a gross margin of € 422,084 and equity of € 319,166. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 25, 2026.
€ 319,166
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 317,166
Profit after tax over the fiscal year.
€ 204,857
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 317,166.
People and assets in 2025
€ 2,860
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 6,044
Supplier invoices still open on the last day of the fiscal year.
€ 103,109
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to BF Resp Oncology?
What happened at BF Resp Oncology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 317,166. Source: NBB ↗
- New establishment in Halle. KBO
- Start of the company according to the CBE. KBO
In short
Paid € 103,109 in corporate taxes since 2025.
A new publication or filing at BF Resp Oncology? We notify you, reason included.
Follow BF Resp OncologyDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind BF Resp Oncology is Bart Jos Forier.
Directors
According to the 2025 annual accounts
Bart Jos Forier
Director
Establishments
Establishment units
Physical locations of this company
Schapenweg 68
3090 Overijse
Ziekenhuislaan 100
1500 Halle
Active since 23 September 2024
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1013.959.311
- VAT number
- BE 1013.959.311
- Registered office
- Schapenweg 68, 3090 Overijse
- Names & denominations
- BF Resp Oncology
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 September 2024
- Peppol
- Active · Active since 2 Sept 2025
- Activities · NACE
Activiteiten van medisch specialisten